SG10201404955RA - Rnai inhibition of alpha-enac expression - Google Patents

Rnai inhibition of alpha-enac expression

Info

Publication number: SG10201404955RA
Authority: SG; Singapore
Prior art keywords: alpha; enac expression; rnai inhibition; rnai; inhibition
Prior art date: 2007-06-15

Application number

SG10201404955RA

Inventor

Heeke Gino Van

Emma Hickman

Henry Luke Danahay

Pamela Tan

Anke Geick

Hans-Peter Vornlocher

Original Assignee

Arrowhead Res Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-15

Filing date

2008-06-13

Publication date

2014-10-30

2008-06-13 Application filed by Arrowhead Res Corp filed Critical Arrowhead Res Corp

2014-10-30 Publication of SG10201404955RA publication Critical patent/SG10201404955RA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG10201404955RA 2007-06-15 2008-06-13 Rnai inhibition of alpha-enac expression SG10201404955RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07110376		2007-06-15
EP07114265		2007-08-13

Publications (1)

Publication Number	Publication Date
SG10201404955RA true SG10201404955RA (en)	2014-10-30

Family

ID=40130244

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201601846VA SG10201601846VA (en)	2007-06-15	2008-06-13	Rnai inhibition of alpha-enac expression
SG10201404955RA SG10201404955RA (en)	2007-06-15	2008-06-13	Rnai inhibition of alpha-enac expression
SG201101084-0A SG169988A1 (en)	2007-06-15	2008-06-13	Rnai inhibition of alpha-enac expression

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201601846VA SG10201601846VA (en)	2007-06-15	2008-06-13	Rnai inhibition of alpha-enac expression

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG201101084-0A SG169988A1 (en)	2007-06-15	2008-06-13	Rnai inhibition of alpha-enac expression

Country Status (26)

Country	Link
US (12)	US7718632B2 (en)
EP (7)	EP2223694B1 (en)
JP (6)	JP5485146B2 (en)
KR (2)	KR101821081B1 (en)
CN (1)	CN101778941B (en)
AR (1)	AR066984A1 (en)
AU (1)	AU2008263876B2 (en)
BR (1)	BRPI0813680A8 (en)
CA (1)	CA2690674C (en)
CL (1)	CL2008001756A1 (en)
CO (1)	CO6251331A2 (en)
CR (1)	CR11136A (en)
CU (1)	CU23774A3 (en)
EA (1)	EA200901653A1 (en)
EC (1)	ECSP099794A (en)
ES (6)	ES2432158T3 (en)
GT (1)	GT200900315A (en)
IL (1)	IL202366A0 (en)
MA (1)	MA31564B1 (en)
MX (1)	MX2009013609A (en)
PE (1)	PE20090942A1 (en)
SG (3)	SG10201601846VA (en)
SV (1)	SV2009003434A (en)
TN (1)	TN2009000521A1 (en)
TW (3)	TWI629063B (en)
WO (1)	WO2008152131A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1532248B1 (en) *	2002-07-26	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Modified small interfering rna molecules and methods of use
KR100473148B1 (en) *	2002-11-27	2005-03-10	(주)텔리언	Interface apparatus and method for burst mode packet transfer
US8765704B1 (en)	2008-02-28	2014-07-01	Novartis Ag	Modified small interfering RNA molecules and methods of use
CA2581651C (en) *	2004-10-01	2014-12-16	Novartis Vaccines And Diagnostics, Inc.	Cholesterol-labelled modified rna
AR066984A1 (en)	2007-06-15	2009-09-23	Novartis Ag	INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
KR20110095391A (en) *	2008-11-26	2011-08-24	머크 샤프 앤드 돔 코포레이션	RNA interference mediated inhibition of epithelial sodium channel (ENNAC) gene expression using short interfering nucleic acids (SINA)
US8563710B2 (en)	2009-04-03	2013-10-22	Biomics Biotechnologies Co., Ltd.	Modified oligonucleotide and its preparation and application
EP2756845B1 (en) *	2009-04-03	2017-03-15	Dicerna Pharmaceuticals, Inc.	Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
CN103275978B (en) *	2009-04-03	2014-10-29	百奥迈科生物技术有限公司	Modified small interfering RNA and preparation method thereof
US20120207818A1 (en) *	2009-07-14	2012-08-16	Shinohara Fumikazu	Composition for suppressing expression of target gene
AU2010306940A1 (en) *	2009-10-12	2012-06-07	Smith, Larry	Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
CN105125572A (en)	2009-12-18	2015-12-09	箭头研究公司	Organic compositions to treat hsf1-related diseases
US8344127B2 (en)	2010-04-23	2013-01-01	Novartis Ag	Organic compositions to treat beta-ENaC-related diseases
CN103703141B (en) *	2011-04-08	2016-08-17	伯乐实验室公司	There is the PCR reactant mixture of the nonspecific activity of reduction
BR112013027070A2 (en)	2011-04-20	2019-09-24	J Smith Larry	methods and compositions for decreasing gene expression using self assembling components in cells and producing RNA activity
KR20140057374A (en)	2011-09-02	2014-05-12	노파르티스 아게	Organic compositions to treat hsf1-related diseases
JP7291624B2 (en)	2016-11-01	2023-06-15	アローヘッドファーマシューティカルズインコーポレイテッド	Alpha-Vbeta-6 integrin ligands and uses thereof
CA3061752A1 (en)	2017-07-06	2019-01-10	Arrowhead Pharmaceuticals, Inc.	Rnai agents for inhibiting expression of alpha-enac and methods of use
PE20200749A1 (en) *	2017-10-31	2020-07-24	Ionis Pharmaceuticals Inc	ENAC EXPRESSION MODULATORS
US11597701B2 (en) *	2017-11-01	2023-03-07	Arrowhead Pharmaceuticals, Inc.	Integrin ligands and uses thereof
CN109364248B (en) *	2018-10-16	2021-05-18	哈尔滨医科大学	Use of ENaC and inhibitors thereof for preventing, alleviating and/or treating atherosclerosis
EP4021413A4 (en) *	2019-08-30	2023-07-05	United States Government as Represented by The Department of Veterans Affairs	LIPOSOMAL FORMULATIONS OF TROPONOID COMPOUNDS
US11957178B2 (en)	2021-11-15	2024-04-16	Apackaging Group Llc	Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4426330A (en) *	1981-07-20	1984-01-17	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4534899A (en) *	1981-07-20	1985-08-13	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) *	1985-10-03	1989-06-06	Rajakhyaksha Vithal J	Transdermal and systemic preparation and method
DE3604625C2 (en) *	1986-02-14	1994-01-20	Bmw Rolls Royce Gmbh	Gas turbine
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5451670A (en) *	1987-12-09	1995-09-19	City Of Hope	Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en)	1988-10-20	1988-11-23	Royal Free Hosp School Med	Liposomes
US5013566A (en) *	1988-12-19	1991-05-07	Sampson Michael James	Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) *	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5356633A (en) *	1989-10-20	1994-10-18	Liposome Technology, Inc.	Method of treatment of inflamed tissues
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5225212A (en) *	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5665710A (en) *	1990-04-30	1997-09-09	Georgetown University	Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (en) *	1991-05-23	2001-10-22	三菱化学株式会社	Drug-containing protein-bound liposomes
JP3351476B2 (en) *	1993-01-22	2002-11-25	三菱化学株式会社	Phospholipid derivatives and liposomes containing the same
ATE192657T1 (en) *	1993-02-19	2000-05-15	Nippon Shinyaku Co Ltd	MEDICINAL COMPOSITION CONTAINING A NUCLEIC ACID COPOLYMER
US5395619A (en)	1993-03-03	1995-03-07	Liposome Technology, Inc.	Lipid-polymer conjugates and liposomes
CA2137297C (en) *	1993-12-06	2000-04-18	Tsuyoshi Miyazaki	Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (en) *	1994-01-24	2004-07-14	日本油脂株式会社	Method for producing igniter granules
US5543152A (en) *	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en)	1995-06-07	1998-05-26	Georgetown University	Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69629702T2 (en)	1995-08-01	2004-06-17	Isis Pharmaceuticals, Inc., Carlsbad	LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS
US5858397A (en)	1995-10-11	1999-01-12	University Of British Columbia	Liposomal formulations of mitoxantrone
US5998203A (en)	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en)	1996-02-21	1999-11-30	The Immune Response Corporation	Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) *	1997-05-16	2001-04-17	Research Corporation Technologies, Inc.	Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) *	1996-08-01	1999-02-02	Wilson-Hyde; Cynthia	Step aerobic platform
US6551775B1 (en)	1997-03-11	2003-04-22	Yale University	Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
JP2002510319A (en) *	1997-07-01	2002-04-02	アイシス・ファーマシューティカルス・インコーポレーテッド	Compositions and methods for delivery of oligonucleotides through the gastrointestinal tract
US5976849A (en) *	1998-02-05	1999-11-02	Zeneca Limited	Human E3 ubiquitin protein ligase
DE60040274D1 (en)	1999-03-10	2008-10-30	Phogen Ltd	ADMINISTRATION OF NUCLEIC ACIDS AND PROTEINS ON CELLS
KR100872437B1 (en) *	2000-12-01	2008-12-05	막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우.	Small RNA molecules that mediate JR interference
BR0209646A (en)	2001-05-16	2006-10-10	Novartis Ag	genes expressed in breast cancer as prognostic and therapeutic targets
WO2003057847A2 (en)	2001-12-31	2003-07-17	Algos Therapeutics , Inc.	METHODS AND MATERIALS FOR MODULATING ENaC-BETA
EP1532248B1 (en)	2002-07-26	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Modified small interfering rna molecules and methods of use
JP2004121218A (en)	2002-08-06	2004-04-22	Jenokkusu Soyaku Kenkyusho:Kk	Method for testing bronchial asthma or chronic obstructive pulmonary disease
GB0218970D0 (en)	2002-08-14	2002-09-25	Creative Peptides Sweden Ab	Fragments of Insulin c-peptide
EP2278005A3 (en) *	2002-11-14	2012-05-23	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
JP2006517092A (en)	2002-11-27	2006-07-20	アルテシアンセラピューティック，インコーポレイティド	Heart failure gene determination and therapeutic drug screening
WO2004050694A1 (en)	2002-11-29	2004-06-17	Basf Aktiengesellschaft	Methods for the production of methionine
DE10305213A1 (en)	2003-02-07	2004-08-26	Florian Prof. Dr.med. Lang	Use of a new polymorphism in the hsgk1 gene to diagnose hypertension and use of the sgk gene family to diagnose and treat Long-Q / T syndrome
US7749491B2 (en) *	2003-03-31	2010-07-06	University Of Iowa Research Foundation	Compounds and methods to enhance rAAV transduction
US7723509B2 (en) *	2003-04-17	2010-05-25	Alnylam Pharmaceuticals	IRNA agents with biocleavable tethers
AU2003224132A1 (en)	2003-04-24	2004-11-19	Galapagos Genomics N.V.	Effective sirna knock-down constructs
US20050256071A1 (en) *	2003-07-15	2005-11-17	California Institute Of Technology	Inhibitor nucleic acids
JP4530335B2 (en) *	2004-02-03	2010-08-25	独立行政法人科学技術振興機構	Inhibitors of epithelial sodium channels expressed in the bladder
KR20070085113A (en) *	2004-05-11	2007-08-27	가부시키가이샤 알파젠	Polynucleotides causing RNA interference, and gene expression inhibition method using the same
SE0402832D0 (en) *	2004-11-18	2004-11-18	Astrazeneca Ab	Methods
US7923206B2 (en) *	2004-11-22	2011-04-12	Dharmacon, Inc.	Method of determining a cellular response to a biological agent
EP1824872B1 (en) *	2004-12-14	2012-02-08	Alnylam Pharmaceuticals Inc.	Rnai modulation of mll-af4 and uses thereof
WO2007051303A1 (en) *	2005-11-02	2007-05-10	Protiva Biotherapeutics, Inc.	MODIFIED siRNA MOLECULES AND USES THEREOF
WO2007070509A2 (en) *	2005-12-13	2007-06-21	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Epithelial sodium channel inhibiting agents and uses therefor
CA2660842C (en)	2006-08-18	2012-03-13	F. Hoffmann-La Roche Ag	Polyconjugates for in vivo delivery of polynucleotides
EP2087110A2 (en)	2006-10-11	2009-08-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Influenza targets
AR066984A1 (en)	2007-06-15	2009-09-23	Novartis Ag	INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)

2008
- 2008-06-12 AR ARP080102518A patent/AR066984A1/en not_active Application Discontinuation
- 2008-06-13 EP EP10163501.9A patent/EP2223694B1/en active Active
- 2008-06-13 EP EP10163499.6A patent/EP2223692B1/en active Active
- 2008-06-13 ES ES10163501T patent/ES2432158T3/en active Active
- 2008-06-13 KR KR1020167023121A patent/KR101821081B1/en active Active
- 2008-06-13 ES ES10163499T patent/ES2432157T3/en active Active
- 2008-06-13 ES ES10163498.8T patent/ES2439277T3/en active Active
- 2008-06-13 EP EP10163500.1A patent/EP2223693B1/en active Active
- 2008-06-13 ES ES10163496T patent/ES2432643T3/en active Active
- 2008-06-13 EP EP10163502.7A patent/EP2223695B1/en active Active
- 2008-06-13 SG SG10201601846VA patent/SG10201601846VA/en unknown
- 2008-06-13 CN CN2008801032623A patent/CN101778941B/en active Active
- 2008-06-13 PE PE2008001013A patent/PE20090942A1/en not_active Application Discontinuation
- 2008-06-13 CA CA2690674A patent/CA2690674C/en active Active
- 2008-06-13 EA EA200901653A patent/EA200901653A1/en unknown
- 2008-06-13 TW TW105120348A patent/TWI629063B/en not_active IP Right Cessation
- 2008-06-13 SG SG10201404955RA patent/SG10201404955RA/en unknown
- 2008-06-13 JP JP2010511658A patent/JP5485146B2/en active Active
- 2008-06-13 AU AU2008263876A patent/AU2008263876B2/en not_active Ceased
- 2008-06-13 EP EP10163496.2A patent/EP2224004B1/en active Active
- 2008-06-13 EP EP08761002A patent/EP2171059A2/en not_active Withdrawn
- 2008-06-13 CL CL2008001756A patent/CL2008001756A1/en unknown
- 2008-06-13 WO PCT/EP2008/057476 patent/WO2008152131A2/en active Application Filing
- 2008-06-13 KR KR1020107000840A patent/KR101653008B1/en active Active
- 2008-06-13 SG SG201101084-0A patent/SG169988A1/en unknown
- 2008-06-13 TW TW097122240A patent/TWI444474B/en not_active IP Right Cessation
- 2008-06-13 MX MX2009013609A patent/MX2009013609A/en active IP Right Grant
- 2008-06-13 EP EP10163498.8A patent/EP2224005B1/en active Active
- 2008-06-13 BR BRPI0813680A patent/BRPI0813680A8/en not_active IP Right Cessation
- 2008-06-13 ES ES10163500T patent/ES2432644T3/en active Active
- 2008-06-13 ES ES10163502T patent/ES2432532T3/en active Active
- 2008-06-13 TW TW103118914A patent/TWI552753B/en active
- 2008-06-16 US US12/140,112 patent/US7718632B2/en active Active
2009
- 2009-11-26 IL IL202366A patent/IL202366A0/en unknown
- 2009-12-02 CR CR11136A patent/CR11136A/en not_active Application Discontinuation
- 2009-12-11 CO CO09142201A patent/CO6251331A2/en not_active Application Discontinuation
- 2009-12-11 GT GT200900315A patent/GT200900315A/en unknown
- 2009-12-11 TN TNP2009000521A patent/TN2009000521A1/en unknown
- 2009-12-11 EC EC2009009794A patent/ECSP099794A/en unknown
- 2009-12-14 SV SV2009003434A patent/SV2009003434A/en unknown
- 2009-12-15 CU CU20090215A patent/CU23774A3/en not_active IP Right Cessation
2010
- 2010-01-06 US US12/683,146 patent/US9074212B2/en active Active
- 2010-01-07 MA MA32484A patent/MA31564B1/en unknown
- 2010-04-30 US US12/771,518 patent/US7939508B2/en active Active
- 2010-04-30 US US12/771,614 patent/US8168606B2/en not_active Expired - Fee Related
- 2010-04-30 US US12/771,566 patent/US8119612B2/en active Active
- 2010-04-30 US US12/771,470 patent/US7943592B2/en active Active
2014
- 2014-02-19 JP JP2014029519A patent/JP5719047B2/en not_active Expired - Fee Related
2015
- 2015-03-19 JP JP2015055783A patent/JP6193906B2/en not_active Expired - Fee Related
- 2015-06-03 US US14/729,104 patent/US9476052B2/en active Active
2016
- 2016-09-09 US US15/260,824 patent/US9914927B2/en active Active
2017
- 2017-08-01 JP JP2017149211A patent/JP6680728B2/en not_active Expired - Fee Related
2018
- 2018-01-18 US US15/874,396 patent/US10544418B2/en active Active
2020
- 2020-01-24 US US16/752,325 patent/US11208662B2/en active Active
- 2020-03-17 JP JP2020046007A patent/JP7157775B2/en active Active
2021
- 2021-12-23 US US17/560,475 patent/US20220112505A1/en not_active Abandoned
2022
- 2022-04-05 US US17/713,763 patent/US20220235361A1/en not_active Abandoned
- 2022-10-07 JP JP2022162309A patent/JP2022188234A/en active Pending

Also Published As

Publication number	Publication date
US11208662B2 (en)	2021-12-28
CR11136A (en)	2010-01-20
US20100216971A1 (en)	2010-08-26
EP2224004A1 (en)	2010-09-01
US7718632B2 (en)	2010-05-18
EP2224004B1 (en)	2013-07-24
EP2223692B1 (en)	2013-07-24
JP5485146B2 (en)	2014-05-07
TWI629063B (en)	2018-07-11
ES2432644T3 (en)	2013-12-04
EP2223694A1 (en)	2010-09-01
SV2009003434A (en)	2011-03-23
KR20100039335A (en)	2010-04-15
JP7157775B2 (en)	2022-10-20
JP2020094063A (en)	2020-06-18
US9914927B2 (en)	2018-03-13
US20200157550A1 (en)	2020-05-21
BRPI0813680A8 (en)	2018-08-28
US20100210513A1 (en)	2010-08-19
MX2009013609A (en)	2010-01-20
ES2439277T3 (en)	2014-01-22
US9476052B2 (en)	2016-10-25
EP2171059A2 (en)	2010-04-07
JP5719047B2 (en)	2015-05-13
US20180148726A1 (en)	2018-05-31
CA2690674C (en)	2018-09-11
JP2022188234A (en)	2022-12-20
US20160376599A1 (en)	2016-12-29
US20220235361A1 (en)	2022-07-28
US8168606B2 (en)	2012-05-01
TW200911989A (en)	2009-03-16
US7943592B2 (en)	2011-05-17
US20150284726A1 (en)	2015-10-08
US8119612B2 (en)	2012-02-21
ECSP099794A (en)	2010-01-29
AR066984A1 (en)	2009-09-23
JP6193906B2 (en)	2017-09-06
US20220112505A1 (en)	2022-04-14
EP2223695B1 (en)	2013-07-24
ES2432532T3 (en)	2013-12-04
CA2690674A1 (en)	2008-12-18
EP2223693A1 (en)	2010-09-01
ES2432643T3 (en)	2013-12-04
TWI552753B (en)	2016-10-11
KR101653008B1 (en)	2016-08-31
IL202366A0 (en)	2011-08-01
GT200900315A (en)	2011-10-05
JP2017222704A (en)	2017-12-21
EP2224005B1 (en)	2013-09-11
TWI444474B (en)	2014-07-11
ES2432157T3 (en)	2013-12-02
SG10201601846VA (en)	2016-04-28
US7939508B2 (en)	2011-05-10
CL2008001756A1 (en)	2009-02-20
WO2008152131A3 (en)	2009-05-28
KR101821081B1 (en)	2018-01-23
EA200901653A1 (en)	2010-06-30
JP2010530369A (en)	2010-09-09
AU2008263876A1 (en)	2008-12-18
JP2014129373A (en)	2014-07-10
TW201636027A (en)	2016-10-16
KR20160105530A (en)	2016-09-06
US20100216972A1 (en)	2010-08-26
SG169988A1 (en)	2011-04-29
EP2223694B1 (en)	2013-07-24
BRPI0813680B1 (en)	2018-02-06
JP6680728B2 (en)	2020-04-15
TW201524510A (en)	2015-07-01
PE20090942A1 (en)	2009-08-05
BRPI0813680A2 (en)	2015-01-06
CO6251331A2 (en)	2011-02-21
EP2224005A1 (en)	2010-09-01
EP2223695A1 (en)	2010-09-01
EP2223692A1 (en)	2010-09-01
CU23774A3 (en)	2012-02-15
US10544418B2 (en)	2020-01-28
US20090156529A1 (en)	2009-06-18
WO2008152131A2 (en)	2008-12-18
US9074212B2 (en)	2015-07-07
MA31564B1 (en)	2010-08-02
ES2432158T3 (en)	2013-12-02
US20100190714A1 (en)	2010-07-29
CN101778941A (en)	2010-07-14
CN101778941B (en)	2013-05-22
TN2009000521A1 (en)	2011-03-31
EP2223693B1 (en)	2013-07-24
AU2008263876B2 (en)	2012-04-12
JP2015145393A (en)	2015-08-13
US20100210514A1 (en)	2010-08-19

Publication	Publication Date	Title
IL202366A0 (en)	2011-08-01	RNAi INHIBITION OF ALPHA-ENAC EXPRESSION
GB0818498D0 (en)	2008-11-19	Provision of inserts
ZA200906946B (en)	2011-05-25	Inhibitors of iap
PT2341943T (en)	2019-02-06	Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
ZA201000318B (en)	2010-10-27	Inhibitors of 11b-hydroxysteroid dehydrogenase
IL199727A0 (en)	2010-04-15	Inhibitors of mek
EP2318395A4 (en)	2011-10-26	Inhibitors of iap
GB201105991D0 (en)	2011-05-18	Anti-tumoural effects of cannabinoid combinations
EP2282755A4 (en)	2015-06-17	Inhibition of angiogenesis
ZA201102604B (en)	2012-09-26	Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
GB0719997D0 (en)	2007-11-21	Portease Inhibition
PL2133419T3 (en)	2019-02-28	Uses of cyanophycin beta-dipeptides
ZA201004765B (en)	2011-09-28	Inhibitors of iap
GB0817926D0 (en)	2008-11-05	Articles of clothiing
GB0916334D0 (en)	2009-10-28	Inhibition of tendon adhesions
GB0701722D0 (en)	2007-03-07	Inhibition of gene expression
GB0724962D0 (en)	2008-01-30	Scale inhibition
GB0802009D0 (en)	2008-03-12	Biomarkers of aminopeptidase inhibition
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
PT2411376E (en)	2015-09-14	Inhibitors of nf-kb
GB201114396D0 (en)	2011-10-05	Location of basesation
GB0702555D0 (en)	2007-03-21	An article of footwaear
ZA200908301B (en)	2010-08-25	Rnai inhibition of alpha-enac expression
HK1141311A (en)	2010-11-05	Rnai inhibition of alpha-enac expression
ZA201000371B (en)	2010-09-29	Article of jewelerry